论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Li C, Yu X, Guo D, Liu G, Zhang K, Teng Q, Lin H
Received 27 November 2017
Accepted for publication 20 April 2018
Published 18 June 2018 Volume 2018:11 Pages 3495—3504
DOI https://doi.org/10.2147/OTT.S158167
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Purpose: Some previous studies have sought to investigate the roles of
excision repair cross complementation group 1 (ERCC1 ), ERCC2 , ERCC4 , and ERCC5 gene polymorphisms in
the prognosis of osteosarcoma patients. However, their results were
inconclusive. Here, we performed a meta-analysis to determine the strength of
the association between eight polymorphisms in the ERCC genes (rs11615,
rs3212986, rs2298881, rs13181, rs1799793, rs1800067, rs2296147, and rs1047768)
and prognosis of osteosarcoma patients treated with chemotherapy.
Materials and
methods: We retrieved the relevant
studies from PubMed, Embase, and Web of Science in human osteosarcoma published
prior to July 2017. Primary outcomes included overall survival (OS) and
event-free survival, expressed by hazard ratios (HRs) with their corresponding
95% CIs. STATA software (version 12.0) was utilized to perform data synthesis.
Results: A total of 13 eligible follow-up studies involving 2,303 patients
met all the inclusion criteria, conducted in two populations of ethnic descent:
11 Asians and two Caucasians. In the present meta-analysis, we demonstrated
that the homozygous variant genotypes in ERCC2 rs1799793
and ERCC5 rs2296147 were
significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR =
0.62, 95% CI = 0.41–0.93, P heterogeneity = 0.310, I 2 = 15.3%, P = 0.020; TT
vs CC for rs2296147: HR = 0.42, 95% CI = 0.23–0.78, P heterogeneity = 0.708, I 2 = 0.0%, P = 0.006). In
addition, no evidence of association was observed between prognosis in
osteosarcoma and ERCC1 rs11615, ERCC1 rs3212986, ERCC1 rs2298881, ERCC2 rs13181, ERCC4 rs1800067, and ERCC5 rs1047768
polymorphisms.
Conclusion: Our meta-analysis indicated that TT genotype in the ERCC2 rs1799793 and ERCC5 rs2296147 might prolong
the survival time of patients with osteosarcoma, suggesting that the rs1799793
and rs2296147 polymorphisms can be used as predictors for prognosis of
osteosarcoma patients treated with chemotherapy.
Keywords: ERCC2 rs1799793, ERCC5 rs2296147,
polymorphisms, osteosarcoma, chemotherapy, prognosis, meta-analysis